VELA Investment Management LLC Has $2.87 Million Stock Position in Supernus Pharmaceuticals, Inc. $SUPN

Posted by Francis Steltz on Sep 8th, 2026

VELA Investment Management LLC boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 25.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 61,703 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,408 shares during the quarter. VELA Investment Management LLC owned about 0.11% of Supernus Pharmaceuticals worth $2,870,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in shares of Supernus Pharmaceuticals by 37.2% during the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after acquiring an additional 193,479 shares during the period. Mystic Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the second quarter worth $1,181,000. BlackRock Inc. acquired a new stake in Supernus Pharmaceuticals in the second quarter worth $434,871,000. Allworth Financial LP acquired a new stake in Supernus Pharmaceuticals in the second quarter worth $2,357,000. Finally, Rice Hall James & Associates LLC bought a new stake in Supernus Pharmaceuticals in the second quarter valued at $22,800,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $43.53 on Tuesday. The company has a market cap of $2.53 billion, a P/E ratio of -22.67, a PEG ratio of 0.80 and a beta of 0.56. The company has a fifty day simple moving average of $46.62 and a 200 day simple moving average of $48.34. Supernus Pharmaceuticals, Inc. has a 12-month low of $42.45 and a 12-month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the previous year, the company posted $0.40 EPS. The business’s quarterly revenue was up 32.4% on a year-over-year basis. Sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Analysts Set New Price Targets

SUPN has been the topic of several research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Read Our Latest Stock Analysis on Supernus Pharmaceuticals

Supernus Pharmaceuticals Profile

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.